State of Wisconsin Investment Board Portfolio holdings
AUM
$40.9B
1-Year Return
24.31%
This Quarter Return
+0.4%
1 Year Return
+24.31%
3 Year Return
+99.94%
5 Year Return
+177.86%
10 Year Return
+427.44%
AUM
$48.3B
AUM Growth
-$73.8M
(-0.15%)
Cap. Flow
+$248M
Cap. Flow
% of AUM
0.51%
Top 10 Holdings %
Top 10 Hldgs %
19.44%
Holding
2,215
New
156
Increased
1,052
Reduced
474
Closed
103
Top Buys
| 1 |
Pfizer
PFE
|
+$92.1M |
| 2 |
Starbucks
SBUX
|
+$65.4M |
| 3 |
J.M. Smucker
SJM
|
+$62.1M |
| 4 |
ARK Innovation ETF
ARKK
|
+$58.7M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$58M |
Top Sells
| 1 |
RDS.B
Royal Dutch Shell PLC ADS Class B
RDS.B
|
+$198M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$111M |
| 3 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
+$103M |
| 4 |
Becton Dickinson
BDX
|
+$78.9M |
| 5 |
American Express
AXP
|
+$74M |
Sector Composition
| 1 | Technology | 23.24% |
| 2 | Financials | 13.95% |
| 3 | Healthcare | 12.7% |
| 4 | Consumer Discretionary | 11.52% |
| 5 | Communication Services | 10.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1701
First Hawaiian
FHB
$3.22B
| $479K | ﹤0.01% |
16,322
+795
| +5% | +$23.3K |
|
1702
CS Disco
LAW
$349M
| $479K | ﹤0.01% |
+10,000
| New | +$479K |
|
1703
Passage Bio
PASG
$22.5M
| $478K | ﹤0.01% |
2,400
+204
| +9% | +$40.6K |
|
1704
Phathom Pharmaceuticals
PHAT
$881M
| $478K | ﹤0.01% |
14,900
| – | – |
|
|
QVCGA
1705
QVC Group, Inc. Series A Common Stock
QVCGA
$78.5M
| $477K | ﹤0.01% |
936
+44
| +5% | +$22.4K |
|
1706
Altimmune
ALT
$322M
| $475K | ﹤0.01% |
42,000
| – | – |
|
1707
Sabre
SABR
$679M
| $472K | ﹤0.01% |
39,878
+1,877
| +5% | +$22.2K |
|
1708
Brighthouse Financial
BHF
$2.8B
| $469K | ﹤0.01% |
10,366
+88
| +0.9% | +$3.98K |
|
1709
Allison Transmission
ALSN
$7.41B
| $466K | ﹤0.01% |
13,185
+175
| +1% | +$6.19K |
|
1710
Adaptive Biotechnologies
ADPT
$1.93B
| $464K | ﹤0.01% |
13,643
+649
| +5% | +$22.1K |
|
1711
FNB Corp
FNB
$5.88B
| $464K | ﹤0.01% |
39,947
+1,981
| +5% | +$23K |
|
1712
Avnet
AVT
$4.49B
| $463K | ﹤0.01% |
12,534
+590
| +5% | +$21.8K |
|
|
JBGS
1713
JBG SMITH
JBGS
$1.43B
| $460K | ﹤0.01% |
15,534
-14,275
| -48% | -$423K |
|
1714
BioAtla
BCAB
$40.5M
| $459K | ﹤0.01% |
15,600
| – | – |
|
1715
Nuvation Bio
NUVB
$1.13B
| $459K | ﹤0.01% |
+46,200
| New | +$459K |
|
1716
BioXcel Therapeutics
BTAI
$54.3M
| $458K | ﹤0.01% |
944
| – | – |
|
1717
Hyatt Hotels
H
$13.6B
| $458K | ﹤0.01% |
5,934
+1,100
| +23% | +$84.9K |
|
1718
Howard Hughes
HHH
$4.68B
| $456K | ﹤0.01% |
5,453
+255
| +5% | +$21.3K |
|
1719
Iovance Biotherapeutics
IOVA
$840M
| $455K | ﹤0.01% |
18,463
+1,121
| +6% | +$27.6K |
|
1720
Frontdoor
FTDR
$4.66B
| $451K | ﹤0.01% |
10,752
-156,195
| -94% | -$6.55M |
|
1721
MSC Industrial Direct
MSM
$5.1B
| $451K | ﹤0.01% |
5,622
+264
| +5% | +$21.2K |
|
|
SPPI
1722
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $441K | ﹤0.01% |
202,300
| – | – |
|
1723
Madison Square Garden
MSGS
$4.95B
| $440K | ﹤0.01% |
2,364
+111
| +5% | +$20.7K |
|
1724
Stoke Therapeutics
STOK
$1.22B
| $440K | ﹤0.01% |
17,300
| – | – |
|
1725
Antero Midstream
AM
$8.78B
| $437K | ﹤0.01% |
41,923
+2,024
| +5% | +$21.1K |
|